The Sequence Radar - Issue 940: Last Week in AI: Opus 5.5 Gets Leaner, Meta Goes Wearable, Washington Talks to Beijing, and Claude Explores DNA
TheSequence Jesus Rodriguez ● Covered by 4 sources
Claude got cheaper and faster for coding, Meta is putting AI in glasses, and Anthropic says its agents found a new DNA enzyme system. The real story: AI is moving from chat boxes into tools, hardware, and labs.
Based on reporting by TheSequence, Jesus Rodriguez — read the original for the full story.
Summary, retelling and take written by AI under human oversight; images are AI-generated illustrations. How we work · Report an error
Anthropic’s Claude Opus 5.5 is the most practical headline in the bunch. The company says it handles coding and knowledge work better than before, while typical workloads cost 40% less than Opus 5 and output generation runs more than 30% faster. That matters because agentic software is only useful if the economics work. When an AI system spends hours inside a codebase, shaving time and cost changes which jobs anyone will hand over in the first place.
Meta is making a different bet: that the next useful AI interface is something you wear. At Connect, it said Muse is coming to its AI glasses in the coming months, along with expanded links to shopping and productivity services and a pocket-sized Muse Charm later this year. It also showed new audio glasses and lightweight VR glasses. The pitch is simple enough. If the model can see what you mean, and can act through the services you already use, there’s less back-and-forth before something gets done.
The week’s geopolitics were quieter, but not by much. Washington proposed a way to notify Beijing about significant AI incidents, and both sides flagged AI as an area for cooperation during this week’s summit. The public record still doesn’t show much in the way of real safeguards. But even a basic channel for incident alerts would be useful, because rivals need some way to tell the difference between an accident and an attack.
Anthropic’s biology work was the strangest and maybe the most interesting piece. The company says Claude agents identified a previously uncharacterized enzyme system with CRISPR-like repeat structures. Roughly 950 agents searched for 21 hours, then human scientists handled the lab work. The enzyme itself had shown up in earlier research, but Claude spotted features around it that were missed before. That is not a finished tool, and nobody should pretend otherwise. It is an early discovery, with a lot of lab work still ahead.
Put together, the week looks like a reminder that model quality is no longer the whole story. Cost decides what gets delegated. Hardware decides where the assistant lives. Diplomacy decides what happens when things go wrong. And experiments decide whether the clever result survives contact with reality.
My take — AI-written commentary, not fact-checked reporting
The industry keeps pretending the model is the product, when it’s really the wrapper, the workflow, and the bill. That’s why the closed-model crowd still loves to talk about “safeguards” while shipping glasses, agents, and lab tools at full speed. The rest is mostly branding with a safety sticker slapped on after lunch.
Read more about this at: TheSequence